Key facts
- This page summarizes Hugh Paul ONeill's Form 4 filing for Keenova Therapeutics plc.
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 26 Feb 2026, 21:01.
Hugh Paul ONeill - 25 Feb 2026 Form 4 Insider Report for Keenova Therapeutics plc
- Reporting relationship
- EVP, Chief Operations Officer
- Issuer ticker
- N/A
- Reported as of
- 25 Feb 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 26 Feb 2026, 21:01:15 UTC
- Prior SEC filing
- 05 Jan 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Mark Tyndall, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Hugh Paul ONeill filed Form 4 for Keenova Therapeutics plc on 26 Feb 2026.
Change
- Previous filing in this sequence was filed on 05 Jan 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0002015073
Primary reporting owner
ONeill Hugh Paul
- Relationship
- EVP, Chief Operations Officer
- Address
- 440 ROUTE 22 EAST, SUITE 302, BRIDGEWATER
- Signature
- /s/ Mark Tyndall, Attorney-in-Fact
- Signature date
- 26 Feb 2026
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
No ticker
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +34,528
- Change %
- +240%
- Price
- $0.000000
- Shares after
- 48,913
- Date
- 25 Feb 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 34,528
- Exercise price
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Upon vesting, each restricted stock unit ("RSU") will be settled in ordinary shares of the Issuer at one share per RSU.
Footnote F2
The RSUs will vest ratably on each of the first three anniversaries of February 25, 2027.
SEC remarks
This Form 4 constitutes a notice to the Issuer for purposes of Part V of the Companies Act 2014.